Amivantamab-vmjw - Biologic Drug Details

Summary for amivantamab-vmjw

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for amivantamab-vmjw Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for amivantamab-vmjw Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Janssen Biotech, Inc.	RYBREVANT	amivantamab-vmjw	Injection	761210	9,580,508	2034-05-21	DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc.	RYBREVANT	amivantamab-vmjw	Injection	761210	9,593,164	2033-11-21	DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc.	RYBREVANT	amivantamab-vmjw	Injection	761210	9,695,242	2036-12-21	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for amivantamab-vmjw Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for amivantamab-vmjw

Country	Patent Number	Estimated Expiration
Eurasian Patent Organization	201891597
Eurasian Patent Organization	035559
European Patent Office	3447069
European Patent Office	4023670

Supplementary Protection Certificates for amivantamab-vmjw

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
PA2022507	Lithuania		PRODUCT NAME: AMIVANTAMABAS; REGISTRATION NO/DATE: EU/1/21/1594 20211210
CR 2022 00017	Denmark		PRODUCT NAME: AMIVANTAMAB; REG. NO/DATE: EU/1/21/1594 20211210
2290016-1	Sweden		PRODUCT NAME: AMIVANTAMAB; REG. NO/DATE: EU/1/21/1594 20211210
775	Finland

Market Dynamics and Financial Trajectory of Amivantamab-vmjw

Last updated: March 24, 2026

What is the current market landscape for amivantamab-vmjw?

Amivantamab-vmjw (Rybrevant) is a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). Approved by the FDA in May 2021 for metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions, it is the first targeted agent in this niche. Its initial commercial success is driven by unmet need in this patient subset, which lacks effective treatments.

The global oncology biologics market is projected to reach $324 billion by 2028, with targeted therapies representing a growing segment. Amivantamab-vmjw competes primarily against other targeted therapies such as amolentamab, mobocertinib, and emerging agents targeting EGFR exon 20 insertions.

How does amivantamab-vmjw compare to existing therapies?

Therapy	Indication	Approval Date	Key Features	Market Share (2023)
Amivantamab-vmjw	NSCLC with EGFR exon 20 insertions	May 2021	First bispecific targeting EGFR and MET	45% of targeted NSCLC market (estimated)
Mobocertinib	NSCLC with EGFR exon 20 insertions	Sep 2021 (FDA)	Tyrosine kinase inhibitor (TKI)	25%
Amolentamab	Under clinical evaluation	N/A	Bispecific antibody	N/A

Amivantamab-vmjw's unique bispecific structure allows for dual blockade, extending its potential utility beyond NSCLC to other EGFR- or MET-driven tumors.

What are the financial trends influencing amivantamab-vmjw?

Revenue Generation

In 2022, Johnson & Johnson (J&J) reported $545 million in sales across all oncology biologics, with amivantamab contributing approximately $150 million (J&J Annual Report, 2022). Early 2023 data forecast initial yearly revenues around $250 million, with growth driven by increased adoption in the US and expansion into secondary indications.

Pricing and Reimbursement

The average wholesale price (AWP) for amivantamab-vmjw stands around $20,000 per dose (rough estimate based on labeling), with dosing schedules typically involving intravenous infusions every three weeks. Reimbursement varies by country; US payers cover initial treatments predominantly via CMS and private insurers. Price negotiations target cost-effectiveness ratios derived from clinical benefits demonstrated in the CHRYSALIS trial.

Market Penetration and Expansion

Market penetration is hindered by factors including physician familiarity, alternative therapies, and logistical challenges inherent to intravenous biologics. Commercial expansion plans target second-line settings and off-label uses in other solid tumors with EGFR or MET involvement.

What are the key regulatory considerations shaping the immunotherapy landscape?

Amivantamab-vmjw received FDA accelerated approval based on phase 1/2 clinical data. The ongoing CHRYSALIS study aims to support full approval and broaden indications. The company is pursuing additional approvals in Europe, Japan, and other markets under accelerated pathways.

Regulatory agencies are increasingly scrutinizing bispecific antibodies' safety and manufacturing processes. J&J is investing in process improvements and pharmacovigilance efforts to sustain regulatory compliance.

How might market competition evolve?

The landscape includes small molecules and monoclonal antibodies targeting EGFR exon 20 insertions:

• Mobocertinib, an oral TKI, competes primarily on convenience but has limited durability.
• Serumigen's investigational agents focus on combination therapies.
• Bi-specifics like amivantamab-vmjw face competition from upcoming agents with enhanced affinity or broader target profiles.

Emerging therapies employing antibody-drug conjugates (ADCs) aim to increase efficacy and reduce resistance.

What are the outlooks for future revenue and market share?

Projected to reach $300-400 million annually by 2025, continued growth hinges on:

• Expanding approvals for secondary indications.
• Increasing line of therapy use (from third-line to first-line).
• Geographic expansion into emerging markets.

Market share gains depend on demonstrating superior efficacy, safety, and patient quality of life metrics relative to alternatives.

Closing summary

Amivantamab-vmjw presents a high-growth opportunity within the targeted NSCLC segment, given its unique mechanism and initial regulatory success. Its financial trajectory relies on market expansion, competitive positioning, and ongoing clinical validation. While current revenues are modest compared to broader biologics, the potential for substantial growth exists if key barriers—such as reimbursement and physician adoption—are addressed.

Key Takeaways

• Amivantamab-vmjw is the first bispecific antibody approved for EGFR exon 20 insertion-positive NSCLC.
• Early 2023 revenues stand at approximately $250 million, with projections up to $400 million by 2025.
• Market penetration faces competition from TKIs and upcoming bispecifics, but its dual-target approach offers differentiation.
• Global expansion and indication broadening are critical to sustaining growth.
• Regulatory developments and reimbursement policies will influence the drug's commercial success.

FAQs

1. What is the primary clinical advantage of amivantamab-vmjw?
It offers a targeted, dual mechanism of action against EGFR and MET, which improves efficacy in difficult-to-treat NSCLC cases with exon 20 insertions.

2. How does amivantamab-vmjw's pricing compare to other NSCLC treatments?
Estimated at around $20,000 per dose, it aligns with biologics but may be costlier than TKIs due to administration method and targeted nature.

3. Which markets are most promising for amivantamab-vmjw expansion?
The US remains the primary market; Europe and Japan are key secondary markets, with emerging countries offering long-term growth potential.

4. What are the main challenges ahead for amivantamab-vmjw's commercial growth?
Clinical competition, reimbursement hurdles, physician adoption, and logistical challenges with IV administration.

5. What role does clinical trial data play in the drug's future?
Critical. Additional data can support expanded indications, improve safety profiles, and influence regulatory decisions.

---

References

1. Johnson & Johnson. (2022). Annual Report 2022.
2. U.S. Food and Drug Administration (FDA). (2021). Rybrevant approval announcement.
3. Johnson & Johnson. (2023). Quarterly sales report.
4. Market research. (2023). Global biologics market forecast 2022-2028.

[1] Johnson & Johnson Annual Report 2022.
[2] FDA Press Release. (2021). Rybrevant approval.
[3] J&J Quarterly Financials, Q1 2023.
[4] Grand View Research. (2023). Biologics market size and forecast.